title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Competing interests | The authors declare no competing interests. | PMC10656569 | ||
References | PMC10656569 | |||
Objectives
| Behcet’s disease | ATHEROSCLEROSIS | To examine the serum irisin level in a group of Behcet’s disease patients, its association with illness parameters, and its utility in diagnosing subclinical atherosclerosis. | PMC9823020 |
Methods | This randomized case–control study included 50 patients and 50 age- and sex-matched controls. Carotid Doppler ultrasound for the measurement of the carotid artery intima-media thickness (CIMT) and ankle-brachial pressure index (ABPI) were performed. A clinical evaluation, lipogram, and serum irisin were also performed. | PMC9823020 | ||
Results | ATHEROSCLEROSIS | Between the patients and the control group, there was a significant difference in CIMT, S. irisin level, and ankle-brachial pressure index; however, gender and BMI did not significantly affect CIMT, ABPI, or S. irisin level. CIMT demonstrated a substantial negative correlation with both S. irisin and ABPI (With a sensi... | PMC9823020 | |
Conclusion | atherosclerosis, Behcet’s illness | ATHEROSCLEROSIS | Subclinical atherosclerosis is prevalent among Egyptian Behcet’s patients, and S. irisin can be employed as a biomarker for diagnosing subclinical atherosclerosis in Behcet’s illness.
• • • | PMC9823020 |
Keywords | Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). | PMC9823020 | ||
Introduction | thrombosis, vascular damage, Vasculitis, inflammation, atherosclerotic, CVD, Behcet’s disease, hyperglycemia, metabolic disease, Behcet’s illness, endothelial cell dysfunction, atherosclerosis, platelet aggregation | CARDIOVASCULAR DISEASE, DYSFUNCTION, INSULIN RESISTANCE, THROMBOSIS, HYPERCOAGULABILITY, PLATELET DYSFUNCTION, ENDOTHELIAL DYSFUNCTION, INFLAMMATION, INFLAMMATORY DISORDER, VASCULAR PROBLEM, METABOLIC DISEASE, CHRONIC SPONTANEOUS URTICARIA, HYPERCHOLESTEROLEMIA, CAROTID ATHEROSCLEROSIS, CVD, VASCULITIS, ENDOTHELIAL DYS... | Behcet’s disease (BD) is a chronic, relapsing, inflammatory disorder characterized by systemic involvement, vascular damage, and endothelial cell dysfunction [Cardiovascular involvement ranges from 7 to 46% [Chronic inflammatory disorders are characterized by systemic inflammation that leads to cardiovascular disease (... | PMC9823020 |
Patients and procedures
| Behcet’s, fasting blood glucose, Behcet Syndrome | STERILE, DISEASE, BEHCET SYNDROME | It is a case–control study that included 50 Behcet’s patients diagnosed according to 2006 classification criteria (ICBD, 2006) [The Ethics Committee of our university’s medical school approved the study under the number IBR ♯ S20-154, and all participants provided written informed permission.All subjects underwent a co... | PMC9823020 |
Evaluation procedure
|
prepare all reagents, working standards, blanks, and samples according to the instructions in the preceding sections.refer to the assay layout sheet to calculate the number of wells to place any unused wells and desiccant back into the pouch, reseal the pouch, and store the wells at 4C.add 50 mL of the standard to the... | PMC9823020 | ||
Diagnostic imaging techniques for atherosclerosis | arterial disease, PAD | PAD, ARTERIAL DISEASE, PLAQUE | A: Carotid Doppler ultrasound, for the measurement of carotid artery intima-media thickness (CIMT): CIMT is defined as a low-level echo gray band that does not project into the arterial lumen. CIMT was measured during the diastolic phase as the distance between the leading edge of the first and second echogenic lines o... | PMC9823020 |
Analytical statistics | Quantitative data were expressed as the mean, standard deviation, median, and range. The student | PMC9823020 | ||
The analysis of regression | atherosclerosis, Behcet’s disease, Behcet’s illness | REGRESSION, ATHEROSCLEROSIS |
Univariate linear regression examination of factors influencing CIMT in Behect’s patients revealed a significant positive relationship with age (Multivariate linear regression analysis of factors affecting CIMT in patients with Behcet’s disease (include significant variable in univariate) revealed that age of patient ... | PMC9823020 |
Discussion | Obesity, CVDs, stroke, atherosclerosis, hyperlipidaemia, atherosclerotic, CVD, cardiovascular lesions, Behcet’s disease, Behcet’s illness, cardiac infarction, T2DM | CARDIAC INFARCTION, HYPERGLYCEMIA, OBESITY, CARDIOVASCULAR DISEASES, CVD, STROKE, DISEASE, HYPERLIPIDAEMIA, CHRONIC INFLAMMATORY DISEASE, REMISSION, INSULIN RESISTANCE, VOGT, REGRESSION, ATHEROSCLEROSIS, TYPE 2 DIABETES, ENDOTHELIAL DYSFUNCTION | Increased risk for cardiovascular lesions (CVD) in patients with pre-existing chronic inflammatory diseases at younger ages observed in some studies raised the assumption about endothelial dysfunction as a common initial lesion in the development of atherosclerosis [There are few studies examining S. irisin as a biomar... | PMC9823020 |
Author contribution | A. I., S. A. | Conceptualization, methodology, supervision, validation, writing evaluation, and editing by Mohamed A. I. Data curation, formal analysis, research methodology, resources, and original draft writing by Ola M. Laboratory analysis, methodology, review, and editing by Ahmed S. The radiological investigation, methodology, v... | PMC9823020 | |
Funding | Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). | PMC9823020 | ||
Data availability | Not available. | PMC9823020 | ||
Declarations | PMC9823020 | |||
Ethical approval | The study was authorized by the Ethics Committee of the faculty of medicine at Sohag university in Egypt, with no IBR ♯ S20-154, and all participants provided written informed consent. | PMC9823020 | ||
Disclosures | None. | PMC9823020 | ||
References | PMC9823020 | |||
1. Introduction | HF, muscle atrophy, human diseases, fatigue, illness, Malnutrition, cancer, inflammation, sarcopenia, Sarcopenia, malnutrition, reduced skeletal muscle mass, heart failure, coronary heart disease, impaired muscle function | MUSCLE ATROPHY, MALNUTRITION, CANCER, INFLAMMATION, SARCOPENIA, FRAGILITY, ADVERSE EFFECTS, SARCOPENIA, MALNUTRITION, HEART FAILURE, CORONARY HEART DISEASE | Background: Malnutrition and sarcopenia frequently affect patients with heart failure (HF), in which clinical outcomes and survival is decreased. Thus, appropriate nutritional screening and early nutrition support are highly recommended. Currently, nutritional support is not a standard of care in patients with HF, and ... | PMC10781070 |
2. Materials and Methods | PMC10781070 | |||
2.1. Patients | end-stage kidney and/or liver disease | MAY | This study was approved by the Ethics Committee of the Reina Sofia University Hospital (Cordoba, Spain; reference number 5164 approved on 21 October 2021 and updated on 30 May 2023). It was conducted in accordance with the Declaration of Helsinki and according to national and international guidelines. This is a prospec... | PMC10781070 |
2.2. Study Design | This was a randomized, open, controlled, clinical trial. Patients were randomly assigned by the clinical investigator to receive either a Mediterranean diet alone or a Mediterranean diet plus two hypercaloric, hyperproteic OSs per day with a 1:1 allocation for twenty-four weeks. Specifically, the OS was composed with a... | PMC10781070 | ||
2.3. Outcomes | high-density lipoprotein | The primary outcome was to evaluate the change in lean mass of patients after both nutritional interventions. Secondary outcomes included changes in other parameters of body composition (fat mass, water, bone, phase angle, body cell mass (BCME), extracellular mass (ECME)); anthropometric parameters (calf, arm, and abdo... | PMC10781070 | |
2.4. Statistical Analysis | PAD | Between-group comparisons were analyzed using the Mann–Whitney U test (nonparametric data). Paired analysis was performed by Wilcoxon test (nonparametric data). The chi-squared test was used to compare categorical data. Statistical analyses were performed using SPSS statistical software version 20, and Graph Pad Prism ... | PMC10781070 | |
3. Results | PMC10781070 | |||
3.1. Baseline Characteristics of the Groups | gastrointestinal symptoms, abdominal pain, sarcopenia, Sarcopenia, malnutrition, weight loss | SARCOPENIA, SARCOPENIA, MALNUTRITION | Thirty-eight patients were included. Most of them were male (71.1%) with a median age of 67.5 y-old. Both groups were comparable in most clinical variables (Significantly, there were no significant differences between baseline LVEF and NT-proBNP levels between both groups. Despite this, control patients tended to compl... | PMC10781070 |
3.2. Primary and Secondary Outcomes | Body weight significantly increased in the whole cohort at the end of the study (79 (69–85) vs. 81 (68–88) kg, No statistically significant differences were observed In abdominal, arm, or calf perimeters after 24 weeks of intervention (According to the RF ultrasound, adipose tissue, muscle area, and muscle circumferenc... | PMC10781070 | ||
4. Discussion | obesity, muscle mass, ankle swelling, fatigue, cardiac cachexia, elevated intra-cardiac pressures, cachexia, inflammation, sarcopenia, reduced cardiac output, cardiac abnormality, HF [, breathlessness, head and neck cancer, malnutrition, Heart Failure | OBESITY, ANKLE SWELLING, MALNOURISHED, PERIPHERAL EDEMA, DISEASE, CLINICAL SYNDROME, SARCOPENIA, INFLAMMATION, MALNOURISHED, HEAD AND NECK CANCER, MALNUTRITION, HEART FAILURE | The European Society of Cardiology defines HF as “a clinical syndrome characterized by typical symptoms (e.g., breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e.g., elevated jugular venous pressure, pulmonary crackles and peripheral edema) caused by a structural and/or functional cardiac a... | PMC10781070 |
5. Conclusions | lean mass gain, sarcopenia, malnutrition | SARCOPENIA, MALNUTRITION | Taken together, our results reveal that a nutritional intervention with the Mediterranean diet in patients with HF results in improvement of functionality, QoL, and cardiac function. Furthermore, the use of a hypercaloric, hyperproteic OS (with slow-release carbohydrates, omega-3, and omega-6) is associated with lean m... | PMC10781070 |
Supplementary Materials | The following supporting information can be downloaded at: Click here for additional data file. | PMC10781070 | ||
Author Contributions | Conceptualization; A.D.H.-M., C.M.J. and M.J.M.P.; Funding acquisition; A.D.H.-M.; Practical performance: M.C.C., J.L.A., A.D.H.-M., G.M.G., C.M.J. and M.Á.G.M.; Formal and data analysis: A.D.H.-M.; Preparation manuscript: A.D.H.-M., M.J.M.P. and C.M.J.; Critical review of manuscript: A.D.H.-M., M.J.M.P. and A.C.C.; Fi... | PMC10781070 | ||
Institutional Review Board Statement | MAY | This study was approved by the Ethics Committee of the Reina Sofia University Hospital (Cordoba, Spain; reference number 5164 approved on 21 October 2021 and updated on 30 May 2023). ClinicalTrials.gov number: NCT05848960. | PMC10781070 | |
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC10781070 | ||
Data Availability Statement | Data are contained within the article. | PMC10781070 | ||
Conflicts of Interest | The authors declare no conflicts of interest. | PMC10781070 | ||
References | sarcopenia | REGRESSION, SARCOPENIA | Schematic overview of the study and treatment arms.Study design.Clinical associations between sarcopenia with age, serum C-RP levels, serum NT-proBNP, and LVEF determined by transthoracic ultrasound. Legend: C-RP: c-reactive protein; ns: non-significative; *: Significant clinical correlations between serum NT-proBNP le... | PMC10781070 |
Background | COMPLICATION | Out-of-plane (OOP) approach is frequently used for ultrasound-guided insertion of central venous catheter (CVC) owing to its simplicity but does not avoid mechanical complication. In-plane (IP) approach might improve safety of insertion; however, it is less easy to master. We assessed, a homemade needle guide device ai... | PMC10543855 | |
Method | We evaluated in a randomized simulation trial, the impact of a homemade needle guide on internal jugular, subclavian and femoral vein puncture, using three approaches: out-of-plane free hand (OOP-FH), in-plane free hand (IP-FH), and in-plane needle guided (IP-NG). Success at first pass, the number of needle redirection... | PMC10543855 | ||
Results | Thirty operators performed 270 punctures. IP-NG approach resulted in high success rate at first pass (jugular: 80%, subclavian: 95% and femoral: 100%) which was higher than success rate observed with OOP-FH and IP-FH regardless of the site ( | PMC10543855 | ||
Conclusion | In this simulation study, IP approach using a homemade needle guide for ultrasound-guided central vein puncture improved success rate at first pass, reduced the number of punctures/redirections and shortened the procedure duration compared to OOP and IP free-hand approaches. | PMC10543855 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s13054-023-04661-w. | PMC10543855 | ||
Keywords | PMC10543855 | |||
Introduction | perforation | Current guidelines recommend ultrasound guidance for central venous catheter (CVC) insertion [For optimal safety, ultrasound-guided CVC insertion requires to visualize the vessel and the needle. Two approaches are available to visualize the needle: the out-of-plane (OOP) approach and the in-plane (IP) approach [Convers... | PMC10543855 | |
Methods | angulation | We designed an open-source 3D printed needle guide to facilitate IP-CVC insertion. The 7.5-MHz linear probe HFL38 available on the M-Turbo® device (Sonosite, Bothewell, MA) was scanned with an EinScan Pro 2X device. Scanning process required two hours per model. We obtained the 3D mold of the probe. The needle guide ma... | PMC10543855 | |
Discussion | injury of posterior venous wall | STERILE | Whereas guidelines actually recommend ultrasound use for CVC insertion, some uncertainty remains for the best approach to use between OOP and IP [Out-of-plane approach is most often used for jugular and femoral CVC insertion owing to its convenience. However, it is associated with risk of injury of posterior venous wal... | PMC10543855 |
Author contributions | Antoine Villa and Eric Maury made substantial contributions in conception, study design and data gathering. Vladimir Hermand performed the process of the 3D printing. Antoine Villa wrote the manuscript. All authors corrected and approved the final version of the manuscript. | PMC10543855 | ||
Funding | No funding for the present study. | PMC10543855 | ||
Availability of data and materials | Datasets were collected on an Xcel file are stored by AV and EM and can be accessed upon request. | PMC10543855 | ||
Declarations | PMC10543855 | |||
Ethical approval and consent to participate | This simulation study was conducted on inanimate manikin and did not require ethical approval. | PMC10543855 | ||
Competing interests | The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript. | PMC10543855 | ||
References | PMC10543855 | |||
Background | T2DM | TYPE 2 DIABETES MELLITUS | Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become firmly established in treatment algorithms and national guidelines for improving glycemic control in type 2 diabetes mellitus (T2DM).To report the findings from a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial, which was designed t... | PMC10563289 |
Methods | T2DM | Patients with T2DM were randomized to receive fotagliptin ( | PMC10563289 | |
Results | hypoglycemia | HYPOGLYCEMIA, ADVERSE EVENTS | After 24 weeks, mean decreases in HbA1c from baseline were -0.70% for fotagliptin, -0.72% for alogliptin and -0.26% for placebo. Estimated mean treatment differences in HbA1c were -0.44% (95% confidence interval [CI]: -0.62% to -0.27%) for fotagliptin versus placebo, and -0.46% (95% CI: -0.67% to -0.26%) for alogliptin... | PMC10563289 |
Conclusions | T2DM | In summary, the study demonstrated improvement in glycemic control and a favorable safety profile for fotagliptin in treatment-naive patients with T2DM. | PMC10563289 | |
Trial registration | ClinicalTrail.gov NCT05782192. | PMC10563289 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s12916-023-03089-x. | PMC10563289 | ||
Keywords | PMC10563289 | |||
Background | T2DM | TYPE 2 DIABETES MELLITUS | The prevalence of type 2 diabetes mellitus (T2DM) has increased markedly with an estimated number of 347 million individuals worldwide in 2008, and forecasted to increase to 7079 individuals per 100, 000 by 2030 [Dipeptidyl peptidase-4 inhibitors (DPP-4i) could improve glycemic control by preventing the rapid degradati... | PMC10563289 |
Methods | PMC10563289 | |||
Study design and randomization | T2DM | TYPE 2 DIABETES MELLITUS | Patients with type 2 diabetes mellitus (T2DM) were randomized to receive fotagliptin, alogliptin or placebo. Subjects who met the inclusion criteria would enter the 4 weeks of placebo run-in period. At the end of the run-in period, a baseline enrollment evaluation was performed. Upon evaluation, all eligible subjects w... | PMC10563289 |
Population | impaired renal or hepatic function, diabetes, T2DM, unawareness | RECURRENT SEVERE HYPOGLYCAEMIA, COMPLICATIONS, DIABETES | Subjects who were 18–75 years old and with previously untreated T2DM (no oral or injected anti-diabetes treatment before 8 weeks of randomisation) were eligible for screening. After a 4-week diet and exercise run-in period, eligible study participants with poor glycemic control (hemoglobin A1c [HbA1c] values of 7.5% to... | PMC10563289 |
Outcomes and assessments | hypoglycemia, T2DM | HYPOGLYCEMIA, EVENTS, SECONDARY, ADVERSE EVENTS | The primary efficacy endpoint was to evaluate the HbA1c from baseline to Week 24 in T2DM patients treated with fotagliptin 12 mg/day, in parallel control with alogliptin and placebo. The secondary endpoints were change in HbA1c from baseline to Week 52; change in FBG from baseline to Week 52; occurrence of hypoglycemia... | PMC10563289 |
Statistical analysis | hypoglycemic | ADVERSE EVENTS | The primary objective was to determine the superiority of fotagliptin over placebo in the change of HbA1c from baseline to Week 24, and the two-sided test of superiority/non-inferiority design was adopted with α = 0.05 and β = 0.20. According to the phase 3 clinical trial results of other drugs in the same class, it is... | PMC10563289 |
Results | T2DM, SD | REGRESSION, EVENTS, SECONDARY, ADVERSE EVENTS | In all, a total of 836 patients with T2DM from 56 sites were screened for eligibility. After the run-in period, 458 patients were randomized in the double-blind period as follows: 230 patients in the fotagliptin group, 113 patients in the alogliptin group, and 115 patients in the placebo group. In the fotagliptin group... | PMC10563289 |
Discussion | T2DM, diabetes | EVENTS, DIABETES | The multicenter clinical study showed that in T2DM patients inadequately controlled with diet and exercise intervention, fotagliptin 12 mg once daily for 24 weeks provided superior glycemic control compared with placebo, as assessed by reductions in HbA1c and FBG. No clinically significant difference in the improvement... | PMC10563289 |
Conclusion | hypoglycemia, weight gain, T2DM | HYPOGLYCEMIA | Overall, the trial demonstrated improvement in glycemic control for fotagliptin monotherapy with 12 mg once daily in previously untreated T2DM patients uncontrolled with lifestyle intervention. Furthermore, fotagliptin treatment was not associated with greater risk of hypoglycemia episodes and weight gain, as compared ... | PMC10563289 |
Acknowledgements | We are indebted to the participants in the present study for their outstanding support and to our colleagues for their valuable assistance. Medical writing and editorial support were provided by Xiangnan Zhou (Clinical Operation Director at Shenzhen Salubris Pharmaceuticals), Chongyang Deng (Medical Manager at Shenzhen... | PMC10563289 | ||
Authors’ contributions | Protocol design: LY, MX, KS and WX. Project Administration: WX and JS. Methodology and Resources: all authors. Data analysis: KS and LY. Validation: all authors. Manuscript writing: KS. Review and editing: all authors. The authors read and approved the final manuscript. | PMC10563289 | ||
Funding | This study was funded by Shenzhen Salubris Pharmaceuticals Co.,Ltd. The study was also funded in part, by grants from the Shenzhen Science and Technology Program for Undertake the National Science and Technology Major Project (CJGJZD20210408091600001). | PMC10563289 | ||
Availability of data and materials | The data that support the findings of this study are available on request from the corresponding authors after the completion of the study. The data are not publicly available due to privacy or ethical restrictions. | PMC10563289 | ||
Declarations | PMC10563289 | |||
Ethics approval and consent to participate | The study was approved by the ethics committee at each study site and conducted according to the Declaration of Helsinki, Guidelines for Good Clinical Practice, and local laws and regulations. All patients provided written informed consents. | PMC10563289 | ||
Consent for publication | All authors believe that the manuscript represents valid work and have reviewed and approved the final version. The work has not been published previously, and is not under consideration for publication elsewhere, in part or in whole. | PMC10563289 | ||
Competing interests | Wenjie Xu and Jingchao Sun were reported being employed at Shenzhen Salubris Pharmaceuticals. The remaining authors declare no competing interests. | PMC10563289 | ||
References | PMC10563289 | |||
Objective | A wide array of methods exist for processing and analysing DNA methylation data. We aimed to perform a systematic comparison of the behaviour of these methods, using cord blood DNAm from the LIMIT RCT, in relation to detecting hypothesised effects of interest (intervention and pre-pregnancy maternal BMI) as well as eff... | PMC9901304 | ||
Methods | DNAm data, from 645 cord blood samples analysed using Illumina 450K BeadChip arrays, were normalised using three different methods (with probe filtering undertaken pre- or post- normalisation). Batch effects were handled with a supervised algorithm, an unsupervised algorithm, or adjustment in the analysis model. Analys... | PMC9901304 | ||
Results | There were differences corresponding to each of the processing and analysis choices. Importantly, some combinations of data processing choices resulted in a substantial number of spurious ‘significant’ findings. We recommend greater emphasis on replication and greater use of sensitivity analyses. | PMC9901304 | ||
Introduction and Background | overweight or obese | DISEASE, EARLY PREGNANCY | With the advent of high-throughput assays, epigenome-wide DNA methylation studies have become more popular, and researchers are now investigating the effects on DNA methylation (DNAm) of a wide range of environmental exposures and physiological conditions, with particular interest in the contribution of epigenetic mech... | PMC9901304 |
Data and Methods | PMC9901304 | |||
The LIMIT randomised controlled trial | LGA | EARLY PREGNANCY | The LIMIT study was a randomised, controlled trial of an antenatal diet and lifestyle intervention for women with early pregnancy BMI ≥25.0 kg/mThe primary outcome of the LIMIT study was birth of a large for gestational age (LGA) infant. There were no significant differences observed between the groups in relation to t... | PMC9901304 |
Probe and sample filtering | The Probes were filtered using multiple criteria. Firstly, probes were excluded if they had a detection Probe filtering was performed either after normalisation (post-filtered) or prior to normalisation (pre-filtered). The one exception for pre-filtering was when normalising using the BMIQ method, where probes on the X... | PMC9901304 | ||
Normalisation | Normalisation involves making changes to the raw data in order to remove artifactual variation. In the case of Illumina 450K BeadChip arrays, this requires correcting for the presence of two different probe types. Infinium I probes use the same colour signal for methylated and unmethylated CpG and are often used for re... | PMC9901304 | ||
Batch effects | Batch effects arise when samples are processed in separate groups, creating unwanted variation due, for example, to different reagents, different plates or different scanner settings (There are 12 Illumina 450K arrays (samples) per chip (this is reduced to eight arrays per chip for the more recent 850K array); thus mos... | PMC9901304 | ||
Flowchart of data processing and analysis. | Combinations of data-processing and analysis choices, consisting of six normalised datasets (SQN, BMIQ or SWAN, with probe filering before or afterwards), use or non-use of ComBat processing (supervised or unsupervised), and analysis with either an unadjusted model, a model adjusted for batch, or a model adjusted for b... | PMC9901304 | ||
Statistical analysis | Differential methylation was investigated probe-wise using linear models with empirical Bayes variance correction as implemented in the For each contrast in each model, the number and identity (where applicable) of any differentially methylated probes (DMPs) were obtained. For detection of DMPs, The findings from diffe... | PMC9901304 | ||
Number of DMPs for infant sex (female), by probe filtering method, batch correction method, normalisation method and cell type method. |
No adjustment beyond the correction for batch as implemented in the ComBat algorithm. | PMC9901304 | ||
DMPs for effect of maternal BMI in the standard care group. | PMC9901304 | |||
DMPs for fake groups: ‘short-haired’ in ‘Tabby’. | PMC9901304 | |||
Probes ranked in top 10 by | For each probe the rank is given by pre- | PMC9901304 | ||
Top 10 probes by LogFC: infant sex. | Largest LogFC for Infant Sex (female), by normalisation and batch correction method. | PMC9901304 | ||
Top 10 probes by LogFC: BMI in standard care. | Largest LogFC for effect of BMI in standard care group, by normalisation and batch correction method. | PMC9901304 | ||
Top 10 probes by LogFC: ‘short-haired’ in ‘Tabby’. | Largest LogFC for effect of ‘Short-Haired’ in ‘Tabby’ group, by normalisation and batch correction method. | PMC9901304 | ||
Distribution of unadjusted P values by normalisation and batch correction method, for batch and cell adjusted models. | Only models from data where probe filtering was performed post-normalisation are included. The model is one adjusting for batch (either explicitly in the model or | PMC9901304 | ||
Distribution of log-fold-change estimates by normalisation and batch correction method, for batch and cell adjusted models. | Only models from data where probe filtering was performed post-normalisation are included. The model is one adjusting for batch (either explicitly in the model or Below we discuss the effect of each dimension (probe filtering, normalisation, batch effects, cell type correction) on results. | PMC9901304 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.